?? Global Brain Health Innovations ??

ESTRADIOL PRODRUGS AND METHODS OF USE THEREOF

#4460506

Inventors:

UNIV MARYLAND

THE US GOV AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS

US HEALTH

Estradiol compounds and methods of using the same for treating diseases and conditions including depressive disorder, an anxiety disorder, post-traumatic stress disorder (PTSD), drug addiction, schizophrenia, Alzheimer's dementia, Parkinson's disease, stroke, traumatic brain injury (TBI), amyotrophic lateral sclerosis (ALS), complex regional pain syndrome (CRPS), chronic pain, neuropathic pain, anhedonia, fatigue, andropause-induced symptoms, and orchiectomy-induced symptoms are provided.

***

Categorization of students with intellectual learning difficulties through analysis of brain activity energy emission

KING FAISAL UNIVERSITY

12142160

An electronic device that detects and analyzes the energy emitted by brains of individuals. This device measures and analyzes the energy emitted from the brain activity of, for example, students, enabling the classification of students with learning difficulties based on the quantity of emitted energy. Leveraging established measuring devices, supported by computer programs akin to those utilized in electrocardiography, enables the prediction of both the quantity and speed of brain energy based on the magnetic field's intensity. By comparing the intensity of the magnetic field resulting from electrochemical energy in the brain with standard measurements for the general populace, learning difficulties can be diagnosed effectively.

BLOOD MARKERS PREDICTIVE OF?BRAIN?PATHOLOGY AND CLINICAL OUTCOME IN PARKINSON'S DISEASE

THE ROCKEFELLER UNIVERSITY

PCT/US2024/028329

The present invention provides biological markers which are molecular markers and predictive of?brain?pathology and clinical status and/or outcome in Parkinson’s disease (PD). The invention provides genes, RNA and protein markers that are associated with, relevant to, or predictive of Parkinson’s disease (PD), Parkinson’s disease with dementia (PDD), Parkinson’s disease with dyskinesia or Parkinson’s disease duration. The present invention further provides methods, kits and markers for the identification and monitoring of disease and disease aspects in Parkinson’s patients and their application as markers and targets in and for evaluating, monitoring and treatment of Parkinson’s disease and relevant pathologies and conditions associated with or developing in Parkinson’s disease.

ENDOGENOUS GENE REGULATION TO TREAT NEUROLOGICAL DISORDERS AND DISEASES

4460568

UCL BUSINESS LTD

OSPEDALE SAN RAFFAELE SRL

The invention provides targeting RNA, single guide RNA, tracrRNA, crisprRNA and expression vectors for use in CRISPR activation (CRISPRa) methods for the treatment of neurological disorders and diseases, in particular epilepsy and pain. In some preferred embodiments, a combinatorial gene therapy approach is used, wherein expression of multiple endogenous human genes are increased in a subject, in order to achieve a greater rescue of seizures and/or behavioural deficits, and restore physiological?brain?function.

TRANSCORNEAL STIMULATOR FOR TREATING?BRAIN?DISEASES

20240374895

City University of Hong Kong

A transcorneal electrical stimulation (TES) apparatus for treating?brain?diseases is provided. The apparatus includes an eye-contacting interface with at least one active electrode, an inactive reference electrode, and a current source. Both the active and reference electrodes are electrically connected to the current source, facilitating transcorneal electrical stimulation for various applications.

GRAPHENE-BASED ELECTRODES FOR ELECTROENCEPHALOGRAM-BASED?BRAIN?COMPUTER INTERFACE SYSTEMS

20240374157

Imam Abdulrahman Bin Faisal University

A?brain-computer interface (BCI) system that includes a cap having wired electrodes selected such as a graphene-based electrode and a reduced graphene oxide (rGO)-coated electrode; a data acquisition and processing unit; and a computing device. The cap is operatively connected to the data acquisition and processing unit via the wired electrodes. The computing device has a communications interface coupled to the data acquisition and processing unit. A method of recording and monitoring?brain?activities of a subject via the BCI system. A method of making the graphene-based electrode and the reduced graphene oxide (rGO)-coated electrode.

CORTICAL SUBARACHNOID AND INTRAVENTRICULAR?BRAIN?INTERFACES

20240374893

William Marsh Rice University

The Board of Regents of The University of Texas System

The present disclosure is directed to neural interface devices and methods that accesses the subarachnoid space to enable minimally invasive modulation and recording of neural structures. Exemplary embodiments may comprise an implantable pulse generator and a microelectrode catheter. In particular embodiments, the microelectrode catheter comprises one or more stimulating and recording electrodes. Exemplary embodiments may also include methods comprising performing a lumbar puncture to access the spinal subarachnoid space and advancing microcatheter through the spinal subarachnoid space.

METHOD FOR CONTROLLING VAGUS NERVE STIMULATION

20240374896

NEURIVE Co., Ltd.

Proposed is a method for controlling vagus nerve stimulation to stimulate the vagus nerves in both ears, in which one or more of intensity (V), a frequency (F), and a pulse width (PW) of electrical stimulation that is applied to both vagus nerves are separately controlled, and the electrical stimulation that is applied to the vagus nerves in both ears is controlled such that a difference of E expressed by the following [Equation 1] becomes 5,000 or more, [Equation 1] E=V2×F×PW. In this case, as units in the equation 1, the intensity is V, the frequency is Hz, and the pulse width is us. There is an excellent effect that not only can improve an effect of vagus nerve stimulation, but also can activate the?brain?connected to the vagus nerve when stimulating the vagus nerve through electrodes being in contact with ears.

NEW ROUTE AND ENGINEERING PROTOCOLS FOR ALZHEIMER'S DISEASE PREVENTION, TREATMENT AND NEURONAL REBUILDING

20240374553

Glycan Industries LLC

Compositions comprising Zinc CARBONYL (ZNCO) and silicon SiHR57 molecules and protocols for their delivery to persons are disclosed, for mitigating and remediating neurodegenerative and cardiovascular diseases. The compositions and protocols are based upon the dissolution properties of neurotoxic compounds accumulated in?brain?tissues, the use of magnetic sources generating external electromagnetic radio waves or fields and the use of quantum tools such as NMRi and MHD-MGD to support molecular flows.

SYSTEMS AND METHODS FOR CHARACTERIZING?BRAIN?ACTIVITY

The Texas A&M University System

20240374217

A method of characterizing?brain?activity includes receiving an electroencephalogram (EEG) output. In addition, the method includes determining a mathematical model of a?brain?using the EEG output, wherein the mathematical model comprises a plurality of ordinary differential equations (ODEs) that are determined based on the EEG output. Further, the method includes characterizing?brain?activity of a subject using the mathematical model.

EXOSOMES FROM COFFEE, GINKGO-BILOBA AND GINSENG

AYE EXOCURE TIBBI üRüNLER SANAYI VE TICARET ANONIM SIRKETI

20240374530

Disclosed is the obtaining of exosomes from coffee, ginkgo-biloba, and ginseng plants and making tablets from the exosomes. The use of plant-derived exosomes obtained from coffee, ginkgo-biloba, and ginseng, with high bio-compatibility, cellular uptake, stability, and much more ability to penetrate the blood-brain?barrier is also disclosed in the treatment of Alzheimer's disease, cognitive dysfunction, forgetfulness, and poor concentration disorders.

GENE THERAPY FOR RETT SYNDROME

PCT/CN2024/092672

Provided are a gene expression cassette containing a polynucleotide sequence encoding a human MeCP2 protein, a viral vector carrying the gene expression cassette, and the use thereof in the treatment of Rett syndrome. One or more binding sites of miRNA are introduced into the provided gene expression cassette, so that overexpression of MeCP2 in?brain?tissue is prevented and the expression of MeCP2 in DRG and the liver is reduced, which solve the possible safety problems caused by the gene therapy.

STROKE DETECTION

AVERTTO MEDICAL LTD

PCT/IL2024/050430

A method for determining changes in?brain?blood circulation, including: recording signals from a single side of a neck; processing the recorded signals; determining hemodynamic changes in?brain?blood circulation indicating abnormal blood circulation at a contralateral side, based on results of the processing.

MULTITARGET CHIMERIC PROTEIN FOR IMMUNOTHERAPY OF ALZHEIMER'S DISEASE

CENTRO DE NEUROCIENCIAS DE CUBA

PCT/CU2024/050004

The present invention is related to the biomedical and biopharmaceutical sectors. Specifically, it relates to a chimeric antigen comprising the combination of the amino and carboxyl terminal regions of the amyloid beta peptide (Aβ), the amino and carboxyl terminal regions of the tau protein and a T cell epitope. The pharmaceutical composition comprising this chimeric antigen and at least one pharmaceutically acceptable vaccine adjuvant increases the efficacy of immunotherapy for the prevention and treatment of Alzheimer's Disease (AD). The chimeric antigen exerts its action by stimulating a multitarget humoral response with high titers of anti-Aβ and anti-tau antibodies simultaneously. This favors the combined elimination of toxic species of both Aβ and tau from the?brain, which prevents or significantly improves the clinical symptoms and neuropathology of AD.

A SYSTEM AND A METHOD FOR DETERMINING COGNITIVE CAPABILITIES BASED ON BRAIN IMAGE

Inteneural Networks Inc.

20240366088

A method for determining cognitive capabilities of a person includes: receiving a brain Magnetic Resonance Imaging (MRI) volume that represents a brain; segmenting the brain MRI volume into white matter, grey matter and cerebrospinal fluid; selecting white matter and/or grey matter from the segmented volume; determining a convex hull shape; computing the contour of the white matter and/or the grey matter shape and the contour of the convex hull shape; and computing a gyrification index based on a comparison of voxels that constitute the contour of the white matter and/or the grey matter and the contour of the convex hull.

INTRANASAL AND OLFACTORY DELIVERY DEVICES AND METHODS OF USE

ROCKET SCIENCE HEALTH

PCT/IB2024/054107

The present disclosure describes devices for intranasal delivery. The devices may have a housing with a dispensing element, and a positioning or trigger element coupled to the housing that engages a columella region of the subject to position the dispensing element within the nasal channel and limit its depth of insertion. The devices can also include two insertable portions, each for insertion into a nasal channel of the subject, and an actuator that delivers the composition from either or both of the insertable portions. The devices can be transitioned from a first configuration to a second configuration. Devices of the present disclosure may provide a convenient and effective way to deliver compositions intranasally and to accomplish lateralized delivery to targeted regions of the brain.

GENE THERAPY COMPOSITIONS AND METHODS FOR REPROGRAMMING GLIAL CELLS

NEUEXCELL THERAPEUTICS (SUZHOU) CO., LTD.

PCT/CN2024/090245

Methods and compositions for producing new neurons in the brain in vivo are provided according to aspects of the present invention which include introducing NeuroD1 alone or in combination with one or more protein factors into a glial cell, particularly into a reactive astrocyte or NG2 cell, thereby converting the reactive glial cell to a functional neuron. Related methods of producing a neuronal phenotype in a glial cell are also provided according to aspects of the present invention which include expressing NeuroDl alone or in combination with one or more protein factors in the glial cell, wherein expressing NeuroDl includes delivering one or more nucleic acid molecules, particularly RNA molecules, formulated as part of lipid nanoparticles to the glial cell.

Physiologic Sensors for Sensing, Measuring, Transmitting, and Processing Signals

20240365098

Phyzio, Inc.

A system includes physiologic sensors and devices. The physiologic sensors sense human physiologic data and the system processes and transmits signals representing the physiologic data. The physiologic data represent at least one physiologic parameter, such as heart rate, respiration rate, blood pressure, body temperature, blood chemistry, other blood constituents, muscle contraction, movement, activity, speech, and brain waves. The system also determines that a device and an object are in proximity to each other, and secures physiologic data at times when the device and object are in proximity to each other, in order to correlate a person's physiologic state while in proximity with or while using the object.

A MEDICAL DEVICE SYSTEM CONFIGURED TO DETERMINE A PROGRESSSION OF PARKINSON'S DISEASE BASED ON SIGNALS COLLECTED BY A MEDICAL DEIVCE IMPLANTED NEAR THE BRAIN

PCT/IB2024/053555

MEDTRONIC, INC.

A medical device system includes an implantable medical device comprising one or more electrodes and accelerometer circuitry, wherein the implantable medical device is configured to be located subcutaneously and proximate to a brain of a patient. The implantable medical device is configured to sense, via the one or more electrodes, a first biometric signal that indicates electrical brain activity of the patient; sense, via the one or more electrodes, a second biometric signal that indicates cardiac activity of the patient; and generate, using the accelerometer circuitry, an accelerometer signal that indicates motion activity of the patient. Additionally, the medical device system includes processing circuitry configured to: determine, based on the first biometric signal, the second biometric signal, and the accelerometer signal, a patient status that indicates a progression of Parkinson's disease over a period of time.

BRAIN FUNCTION IMPROVING AGENT

4454483

Inventor: UNIV OSAKA

MITSUI NORIN KK

The present invention pertains to a brain function improving agent for preventing the onset of, treating, and/or ameliorating cognitive function impairment and depressive symptoms in central nervous system diseases, the agent being characterized by containing as active ingredient, at least one among 5-(3,5-dihydroxyphenyl)-γ-valerolactone represented by formula (I), a salt of said compound, and a conjugate of said compound.

METHOD FOR INFERRING A CHANGE IN A WHOLE-BRAIN NETWORK AND SYSTEM

PCT/EP2024/060977

The invention relates to a method for inferring a change in a whole-brain network in a brain of a mammal. The method comprises the steps of providing a computerized platform modelling various regions of a mammal brain and connectivity between these regions; providing three-dimensional anatomical structural imaging data of the brain of the mammal; providing a parametric mathematical neural model describing an evolution of the neural field in a brain of a mammal; providing magnetic resonance imaging time-series data of the brain; fitting the model with the magnetic resonance imaging time-series acquired; estimating the parameters of the model; inverting the model; and inferring the change in the whole-brain network in the mammal ' s brain.